{"brief_title": "Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma", "brief_summary": "The primary purpose of this protocol is to determine the activity of AG 013736 in patients with metastatic renal cell cancer who have received 1 prior cytokine-based therapy.", "condition": ["Kidney Neoplasms"], "intervention_type": ["Drug"], "intervention_name": ["Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor"], "criteria": "Inclusion Criteria: - Histologically documented RCC with metastases. - Failure of 1 prior cytokine-based therapy (interleukin-2 and/or interferon) due to disease progression or unacceptable treatment-related toxicity Exclusion Criteria: - Any prior systemic treatment for Renal Cell Carcinoma [RCC] other than 1 prior cytokine-based treatment regimen. Cytokine-based regimens containing thalidomide or an anti-angiogenesis agent are not allowed. - Inability to take oral medication", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Kidney Neoplasms", "Endothelial Growth Factors", "Axitinib", "Mitogens"], "id": "NCT00076011"}